Trials / Completed
CompletedNCT03999853
Butyrate Adjuvant Therapy for Type 1 Diabetes
Colonic Delivery of Butyrate to Improve Insulin Sensitivity and Lower Triglycerides in Type 1 Diabetes Subjects
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The investigators are interested to evaluate the effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy on metabolic control in type 1 diabetes (TID) subjects.
Detailed description
This study will test effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy in type 1 diabetes (TID) Subjects on metabolic control in this population. Insulin sensitivity, glucose control (variability) and triglycerides will be measured after 7 weeks of treatment and compared to baseline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BKR-017 | BKR-017 |
Timeline
- Start date
- 2022-07-28
- Primary completion
- 2025-04-01
- Completion
- 2025-12-01
- First posted
- 2019-06-27
- Last updated
- 2026-03-31
- Results posted
- 2026-03-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03999853. Inclusion in this directory is not an endorsement.